Singapore draws international biotech VCs as Asia-Pacific life sciences sector takes off
Trump’s tariffs may prompt firms to reassess investments, but the sector’s long-term outlook is unlikely to change
Add BT as a preferred source
In this series, The Business Times delves into the state of Singapore’s biotech scene, exploring a key challenge: converting its world-class research and development output into commercial victories.
While our first story looked at the reasons behind why few home-grown companies are listing on the Singapore Exchange, this instalment looks upstream and finds a more vibrant picture as international biotech venture capital firms head to Singapore. Upcoming stories will explore the macroeconomic headwinds facing the sector and the future direction of the industry.
[SINGAPORE] International biotech venture capital (VC) firms are flocking to Singapore, drawn by the Asia-Pacific region’s growing life sciences sector, with one more European VC confirmed to set up operations before year-end.
TRENDING NOW
Not retirement, but a rewiring and fresh perspectives post-DBS, says Piyush Gupta
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Hong Kong’s bad-debt bankers ramp up fire sales, liquidations as city’s distressed loan ratio hit a high
Power of payouts: A big chunk of the STI has just gone ex-dividend. What’s next?
